Saltar al contenido
Merck

Vanillin enhances TRAIL-induced apoptosis in cancer cells through inhibition of NF-kappaB activation.

In vivo (Athens, Greece) (2010-07-30)
Kriengsak Lirdprapamongkol, Hiroaki Sakurai, Shunsuke Suzuki, Keiichi Koizumi, Orawin Prangsaengtong, Amornrat Viriyaroj, Somsak Ruchirawat, Jisnuson Svasti, Ikuo Saiki
RESUMEN

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent which selectively kills cancer cells with little effect on normal cells. However, TRAIL resistance is widely found in cancer cells. We have previously reported antimetatstatic and antiangiogenic effects of vanillin, a flavoring agent from vanilla. Here we have evaluated the sensitizing effect of vanillin on a TRAIL-resistant human cervical cancer cell line, HeLa. Cell viability after treatments was determined by the WST-1 cell counting kit. Apoptosis was demonstrated by detection of caspase-3 activation and cleavage of poly (ADP-ribose) polymerase using immunoblot analysis. Effect of treatments on TRAIL signaling pathway and nuclear factor kappaB (FN-kappaB) activation was studied using immunoblot analysis and luciferase reporter assay. Pretreatment of HeLa cells with vanillin enhanced TRAIL-induced cell death through the apoptosis pathway. Vanillin pretreatment inhibited TRAIL-induced phosphorylation of p65 and transcriptional activity of NF-kappaB. Vanillin sensitizes HeLa cells to TRAIL-induced apoptosis by inhibiting NF-kappaB activation.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Vainillina, ≥97%, FCC, FG